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Immunochemistry of urinary calcium oxalate crystal growth inhibitor
(CGI). Calcium oxalate crystal growth inhibitor (CGI) was isolated from
human urine in monomeric form (14,000 daltons). Antibody was elicited
and purified to monospecificity by affinity chromatography. Tamm—
Horsfall protein was isolated from human urine and an antibody to
Tamm—Horsfall protein compared to anti-CGI. The anti-COl reacted
with its antigen on immunodiffusion, by ELISA and by Western
Blotting of polyacrylamide gel electrophoresis—separated antigen. Im-
munofluorescent localization of CGI was found in distal renal tubules.
This was precisely the localization of Tamm—Horsfall protein. Isolated
Tamm—Horsfall protein was found to bind CGI which could only be
partially removed with EDTA. While anti-CGI is suitable to assay CUl
in human urine by ELISA techniques, it will also detect CGI that is
complexed to THP. While the CGI found in human urine possesses 90%
of the urinary macromolecular crystal growth inhibitor activity, THP is
without effect on crystal growth, in spite of bound CGI. The balance
between free CGI and that bound to Tamm—Horsfall protein may be
important in the overall balance of urinary macromolecules that affect
calcium oxalate nephrolithiasis.
The pathogenesis of kidney stone disease seems to involve a
breakdown of the normal balance between urinary supersatu-
ration with respect to calcium oxalate and urinary inhibitors of
calcium oxalate crystal nucleation and growth [1]. The inhibi-
tors have been variously described as mainly urinary small
molecules [21 and macromolecules [3]. Zerwekh, Holt, and Pak
[3] have studied the effect of the different fractions of urinary
macromolecules on calcium oxalate crystal nucleation as well
as their relative amounts in the urine of stone formers and
normal persons, and concluded that glycosaminoglycans were
important in reducing calcium oxalate crystallization. Coe et al
have isolated from human urine [4] and from human kidney
tissue culture medium [5] and from rat kidney and urine [6] a
14,000 MW glycoprotein (CGI) which seems to be responsible
for up to 90% of the urinary macromolecular crystal growth
inhibitory activity. The role of Tamm—Horsfall (THP) glycopro-
tein in the pathogenesis of stone formation has not been
clarified. Rose and Sulaiman [7] have suggested that THP can
promote calcium oxalate crystal nucleation, but that it seemed
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to be without effect on crystal growth [8]. We developed
antibodies to CGI, suitable for immunoassay, and found that a
relationship appeared to exist between the CGI and THP which
may be important in the overall balance of urinary macromol-
ecules that affect calcium oxalate nephrolithiasis. We were also
able to provide the first evidence for the co-localization of these
proteins within the distal renal tubular cells.
Methods
Antigens
Human urinary calcium oxalate monohydrate crystal growth
inhibitor (CGI). The calcium oxalate monohydrate crystal
growth inhibitor was purified from urine of a normal adult male
as described previously [4]. A monomeric form (mole wt 1.4 x
l0) was prepared after incubation for four days in 0.05 M
EDTA, pH 7.8, then passed through a Sephacryl S-200
(Pharmacia, Piscataway, New Jersey, USA) column (2 X 110
cm) using 0.05 M Tris HCI, 0.2 M NaC1, 0.02% NaN3 as a
solvent. An aggregated preparation of CGI (mole wt 6.4 x l0)
was isolated by a similar manner as described above without
EDTA treatment.
Tamm—Horsfall glycoprotein. Tamm—Horsfall glycoprotein
(THP) was isolated from 10 liters of pooled human urine initially
according to the method described by Tamm and Horsfall [9].
The THP was precipitated from pooled urine by adding NaCI to
0.58 M at pH 5.0 and stirred overnight at 4°C. The precipitate
was collected by centrifugation (10,000 g x 20 mm). The
precipitate was dissolved in water, 1/10 volume of the original
urine volume, and the 0.58 M NaC1 precipitation repeated. The
THP fraction was dissolved in 10 m sodium phosphate buffer
(pH 7.2) containing 4 M urea, and further purified by Sepharose
4B (1.6 x 60 cm) chromatography in the same buffer. The THP
was dialyzed against 6 liters of deionized water at 4°C with two
changes, then lyophilized.
Antibodies
Two male New Zealand white rabbits were immunized with
one mg of a CGI preparation, either aggregated or monomeric,
in complete Freunds adjuvant (Difco, Detroit, Michigan, USA),
divided between popliteal nodes and foot pad. Booster injec-
tions were given after three and six weeks. Pooled bleeds were
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obtained over one week, seven to ten days after the booster
injections.
The IgO fractions of antisera were isolated by 50% NH4
(SO4)2 precipitation and ion exchange chromatography (DES3,
Whatman, Clifton, New Jersey, USA) [10] and concentrated to
10 mg/muter (Amicon XM-100, Danvers, Massachusetts,
USA). Antibody to human THP was previously reported [11].
Analytic methods
Enzyme—linked immunoassay (Streptavidin—ELISA) was
performed as previously described [121 using Streptavidin—Bio-
tin detection (BRL, Bethesda, Maryland, USA). Antigens were
coated in carbonate buffer, pH 9.6 at 4°C overnight in 96—well
microtiter plates (Flow Laboratories, Inc., McLean, Virginia,
USA). The primary antibody was diluted in phosphate buffered
saline with 0.05% BSA (PBS—BSA) and incubated for one hour.
The secondary antibody was biotinylated goat anti rabbit Ig
(GaRG) (E.Y. Laboratories, San Mateo, California, USA)
diluted 1:1000 in 1% BSA in PBS, incubated for 45 mm.
Detection was with 0.04% o-phenylenediamine dihydrochlo-
ride, 0.012% H202 in citrate/phosphate buffer pH 5.0. The
absorbance was measured at 450 nm at 10 mm and 20 mm with
a titertek Multiskan MicroElisa Reader (Flow Laboratories,
Inc., McLean, Virginia, USA). Streptavidin—ELISA—inhibition
was performed as described [12].
Immunodiffusion studies were performed on 3 x 1 inch
microslides prepared with 3 mliters of 1.5% Agarose (Marine
Colloids, Inc., Rockland, Maine, USA) in glycine—saline buffer
pH 8.2. Once the immunodiffusion was completed, the plates
were washed with normal saline overnight and stained with
amido black.
Polyacrylamide slab gel electrophoresis was performed in
discontinuous buffers with 0.1% SDS (SDS—PAGE) [131. AS to
15% linear gradient of acrylamide concentration was used. The
gels were silver—stained according to the method described by
Wray et al [14]. The proteins were applied to the gel both in
their native form and also after dialysis against 0.05 M EDTA at
4°C for four days.
A nitrocellulose spot test was used to test solid phase
antibody reactivity to antigens before and after treatment with
SDS and with 2-mercaptoethanol applied directly to nitrocellu-
lose (Whatman NC paper, Clifton, New Jersey, USA). All of
the antigens were tested at concentrations of 0.06, 0.25, 1.0 and
4.0 mg/mliter. Reactivity was detected with biotinylated GaRG
(E.Y. Laboratories), Streptavidin-HRP (BRL) and 0.024%
diaminobenzidine, 0.3% H2O2, 0.OS M Tris buffer pH 7.4 for 20
mm.
The Western Blotting of proteins from polyacrylamide gel to
NC paper was performed as described by Burnett [15] and
Towbin [16]. The reactivity of the antigens with the anti-CGI
was detected by the same method described in the nitrocellu-
lose spot test.
Affinity purified anti-COl (AFaCGI) was prepared with two
mliters of the activated affinity support, Affi-gel 10 (Biorad,
Richmond, California, USA) coupled according to the manu-
facturer's directions with 0,9 mg of the purified monomeric
CGI. Antibody was bound in PBS and eluted with 0.1 M
glycine—saline, pH 2.8, immediately neutralized with 1 M Tris to
pH 7.0.
Immunofluorescence microscopy
Frozen sections of normal human kidney were cut at 2 to 4
tm in a dehumidified environment and stored at —20°C. The
tissue was overlaid with antisera, IgG fractions or affinity—puri-
fied antibody at serial dilutions (1:4 to 1:1000) and then stained
with goat anti-rabbit IgG human—labelled with fluorescein iso-
thiocyanate (FITC), (FGaRG), or rhodamine (RGaRG) (Cappel
Laboratories, Inc., Cochranville, Pennsylvania, USA) ab-
sorbed with human plasma as previously described [17]. Renal
cortical slices were prepared with no primary antibody as a
negative control.
Results
Immunohistologic studies
The antibodies raised against the monomeric CGI reacted
only with the distal nephron, specifically, the distal part of the
ascending limb of Henle and the distal convoluted tubule (Fig.
1). The macula densa itself was negative. A direct comparison
of this localization to that of THP [11, 18] was obtained with
adjacent, frozen sections stained with RaTHP and RGaRG.
Both staining patterns were identical. The pattern of AFaCOI
was also identical.
Antisera that were elicited to the aggregated inhibitor showed
other (contaminating) determinants, and also reacted with the
brush border of the proximal tubule, the parietal epithelium of
Bowman's capsule, and within Bowman's space in some
glomeruli. With progressive dilution of these sera, the localiza-
tion to the proximal nephron was lost, while it clearly persisted
in the more distal regions. While the ELISA reactivity with CGI
was identical to that of the monomeric antibody, these (impure)
antisera were not explored further.
Linear immunodiffusion
The antibody raised against the monomeric inhibitor gave one
immunoprecipitation line against both the aggregated (not
shown) and the monomeric forms of the inhibitor as well as with
THP, giving one line of identity between the three antigens.
Anti-THP reacted against native THP and the monomeric
Fig. 1. Immunofluorescent localization of aCGJ on human renal cortex,
to distal tubule, adjacent to unstained glomerulus (G). Proximal tubules
(P) are also unstained. (x200)
Immunochemistry of CGI
0.300
0.250
100
90
80
70
60
50
40
30
20
10
831
Fig. 5. Streptavidin-ELISA inhibition curve against monomeric CGI
(ng/well).
Fig. 3. Immunodiffusion of aTHP (2, 4, 6) at 1:4 dilution and aCGI (1,
3,5) at dilutions of 1:1 (1), 1:4(3) and 1:16(5) against THP (treated with
EDTA). Note the single determinant identified by aCOl and two
determinants of aTHP.
inhibitor with a single line of identity at all dilutions. When THP
was treated with EDTA, there appeared two distinct immuno-
precipitation lines (Fig. 2). One of these lines was continuous
with the line between anti-THP and the monomeric inhibitor at
all dilutions (Fig. 3). Treatment of monomeric and the aggre-
gated inhibitors with EDTA did not alter the single immunopre-
cipitin line common to anti-THP and anti-inhibitor.
Characterization of the aCGI by streptavidin-ELISA
The optimal coating concentration for the monomeric antigen
was determined to be 1 pg/well. At this concentration the
reactivity of aCGI was present up to a 1:30,000 dilution, and the
AFaCGI at 1:20,000 (Fig. 4). For inhibition assays, the optimal
dilution of the antibody was 1:1000. The curve obtained with
the monomeric stone inhibitor as the antigen showed progres-
sive binding inhibition in the range between 25 and 200 ng/100
j.diter of antibody (Fig. 5).
THP partially inhibited the Streptavidin-ELISA titer of aCGI
(Fig. 6). This inhibition was altered by treatment with EDTA.
When native THP was incubated with the anti-CGI at 1:1000,
ELISA inhibition was never lower than 30%. When THP was
treated with dialysis against 0.01 M EDTA and then employed
as inhibiting antigen, the binding dropped below 10%, and thus
inhibition was almost complete (Fig. 6).
Normal urine was incubated with aCGI at concentrations
ranging from 0.5 to 20 piiter!100 p,liter antibody at 1:1000
dilution (Fig. 7). The inhibition with the normal urine was
almost complete at 20 diter/piiter with a percent binding of less
than 10%. The 50% inhibition point (4 diter urine) cone-
sponded to 100 ng CGI, suggesting a concentration of 25
g/m1iter.
Fig. 2. Immunodiffusion of aCOl and aTHP against monomeric CGI
and THP treated with EDTA. Note that aCGI reacts with THP in spite
of EDTA treatment of THP (1) identical with the reaction to CGI. In
addition, aTHP reacts with another determinant of THP (3) not identi-
fied on CGI (2).
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Fig. 4. Streptavidin-ELISA titer of Aff aCGI against monomeric CGI, I
/sg per well.
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Fig. 6. Inhibition of Streptavidin-ELISA (CGI at I jig/well vs. aCGI at
1:1000) by THP and THP treated with EDTA at 10 to 2000 jig/well.
100
Gel electrophoresis
Monomeric CGI, aggregated CGI, THP and concentrated
normal urine were analyzed by SDS-PAGE both in their native
form and after treatment with EDTA.
In native forms, the monomeric (Fig. 8, lane 2) and the
untreated CGI were found primarily in the 14,000 dalton band.
The untreated CGI (not shown) had two additional minor
bands, one at approximately 68,000 daltons, which is compati-
ble with the aggregated material as described by Nakagawa et al
[4], and the other at 84,000 daltons in the region of THP. After
treatment with EDTA, the untreated form of CGI showed
enhancement of the 14,000 dalton band.
Native THP migrated almost entirely at the 84,000 dalton
region. The appearance of THP was strikingly different after
treatment with EDTA in that it showed a distinct band at the
14,000 molecular weight region (Fig. 8, lane 3). In urine,
multiple bands were seen, but with EDTA treatment there was
an increase in the intensity of a band at the 14,000 dalton region
(not shown).
Nitrocellulose detection of aCGI reactivity
The nitrocellulose paper reactivity (spot test) of CGI with
aCOl at concentrations as low as 0.06 mg/muter, demonstrated
that the reaction was resistant to denaturation by SDS. Reduc-
tion (2-mercaptoethanol) abolished reactivity with anti-inhibitor
antibody only below concentrations of 0.25 mg/mliter. Like-
wise, TRP showed persistence of reactivity with aCGI at
concentrations as low as of 0.06 mg/muter. After treatment with
SDS and 2-mercaptoethanol, concentrations of THP below 0.25
mg/mliter were not visualized.
Western blotting of antigenic reactivity
The aCGI at 1:500 reacted with monomeric CGI, aggregated
CGI and THP—separated by SDS—PAGE in the presence of
2-mercaptoethanol.
After affinity purification on CGI that had no detectable THP
by silver stain (Fig. 8, lane 2), AFaCGI likewise reacted with
this antigen in the 14,000 dalton band, and another band at
approximately 50,000 daltons (Fig. 8, lane 5) that was not
visible in the silver—stained gel (Fig. 8, lane 2). After treatment
with EDTA, THP showed reactivity not only at 14,000 daltons,
but in the 84,000 dalton "THP" band.
Discussion
We have developed a monospecific antibody to the major
inhibitor of calcium oxalate crystal growth (CGI) from human
urine. The antibody reacts with the antigen by immunodiffu-
sion, ELISA, ELISA inhibition, and Western blotting of the
purified antigen. The antigen used for affinity—purification of the
antibody had no detectable impurities on overloaded gels, using
a sensitive silver stain.
The aCGI localized by immunofluorescence to the renal distal
tubule, which was precisely that seen with antibody to Tamm—
Horsfall glycoprotein (THP) [11, 18]. This suggested that CGI
might be related to THP even though isolated THP was without
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Fig. 8. SDS-FAGE in the presence of 0.05 M EDTA. Silver stained
(lanes 1, 2, 3) and Western blot (lanes 4, 5, 6) with AFaCOI.
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effect on calcium oxalate crystal growth [8]. In order to verify
that the antibody did not react with THP, it was affinity—purified
on CGI that had no detectable trace of THP. Nevertheless, this
antibody still reacted on immunodiffusion with THP. In addi-
tion, after Western blotting, the AFaCGI reacted not only with
CGI but with the 84,000 dalton band of THP. Incubation of THP
with EDTA, which had disaggregated CGI into monomers of
14,000 daltons, resulted in the appearance of a 14,000 dalton
band in the THP preparation that reacted with AFaCGI. How-
ever, the 84,000 dalton (THP) band continued to react with
AFaCGI. Thus we were unable to completely separate the CGI
antigen from THP.
By Streptavidin-ELISA, aCGI reacted appropriately with
CGI and was inhibited by fluid—phase absorption with CGI.
THP partially inhibited the reaction with CGI. After treatment
of THP with EDTA, it inhibited the reaction of CGI with aCGI
more completely, suggesting that there is a partial blocking of
the CGI antigen when bound to THP.
Concentrated human urine was successfully assayed for
inhibition of Streptavidin-ELISA reactivity. Nevertheless, this
assay would also detect the CGI antigen bound to THP. In
order to separately assay CGI and THP, studies are in progress
to use affinity chromatography to remove anti-CGI activity
from anti-THP. The anti-THP used here clearly also had
reactivity with CGI, which may be the case with other antibod-
ies used for assay of THP [19, 20]. In that antibodies to THP
may react with CGI, the apparent presence of THP antigen in
serum [21] could actually reflect CGI or another antigen [22].
The precise relationship between CGI and THP could not be
determined by the present studies. In normal urine, CGI may be
partially bound to THP, and may therefore have a different
effect on calcium oxlate crystal growth than that of the unbound
inhibitor. The net inhibition of crystal growth could depend in
part upon that binding, whose equilibrium may depend upon
other urinary ionic constituents.
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